Abstract 672P
Background
CDK8 and its paralog CDK19 are part of the mediator complex connecting enhancers and core promoters and regulating genes responsible for oncogenic transformation and differentiation. RVU120 is a selective CDK8/19 inhibitor, currently in phase 1 clinical development. RVU120 showed strong anticancer activity in non-clinical cancer models.
Methods
In the ongoing phase I/II study (NCT05052255), patients with metastatic or locally advanced solid tumors receive RVU120 until disease progression or unacceptable toxicity. Primary objectives are safety, tolerability, and determination of the recommended phase 2 dose. Secondary objectives include ORR, pharmacokinetic and pharmacodynamics. Molecular response to RVU120 is assessed by genetic profiling of tumor biopsies and ctDNA. NanoString technology is used for transcriptional profiling of tumor biopsies.
Results
As of 01 May 2023, there were 30 patients treated across 7 cohorts (75 - 375 mg). The most frequent AEs were nausea and vomiting, all were G1 or 2. No patient experienced a DLT, 10 SAEs were reported in 6 patients (worsening of tumoral pain, urinary tract infection, medullary compression, lower GI bleeding, worsening of basal ataxia/dizziness, renal calculi, stroke). One patient died following an SAE of general physical health deterioration due to PD. No SAE was considered IMP related. A total of 15 patients had at least 1 RECIST assessment: 2 PD (21% and 26% increase in TL size), 13 radiologic SD (between -4% and +11% change in TL size). Out of these, a patient with refractory pancreatic cancer achieved a reduction of CA19.9 on 3 consecutive time points and radiologic SD after cycle 3. Pharmacodynamic profiling of all patients revealed target engagement of >70% at doses up to 375 mg. Data from genetic and transcriptomic profiling will be presented.
Conclusions
After 7 dose levels with single agent RVU120 (up to 375 mg), a favorable safety profile was observed. Most TEAEs were mild/moderate, no DLTs nor IMP related SAEs were reported. RECIST assessments of 15 patients demonstrated radiologic SD in 13 patients. Dose escalation is currently ongoing with PK modeling indicating high target engagement.
Clinical trial identification
NCT05052255.
Editorial acknowledgement
Legal entity responsible for the study
Ryvu Therapeutics SA.
Funding
Ryvu Therapeutics SA.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
116P - Circulating tumour DNA- based minimal residual disease detection for biliary tract cancer
Presenter: Zhishuai Li
Session: Poster session 17
117P - Genomic landscape of biliary tract cancers from India show distinct geographic variation
Presenter: Nitesh Rohatgi
Session: Poster session 17
118P - Artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker for anti-PD-1 in advanced biliary tract cancer (BTC)
Presenter: Yeonghak Bang
Session: Poster session 17
119P - Management of biliary tract cancers in older patients: A French multicenter cohort study
Presenter: Marine Valery
Session: Poster session 17
120P - Management of biliary tract cancers in early onset patients: A French multicenter real-life study from the ACABI-PRONOBIL cohort
Presenter: Antoine Lebeaud
Session: Poster session 17
121P - PemiBil: Efficacy and safety of pemigatinib in advanced cholangiocarcinoma with FGFR2 fusions/rearrangements in real-world, results of multicentric French cohort from ACABI consortium
Presenter: Blandine Delaunay
Session: Poster session 17
122P - Largest examination of cholangiocarcinoma (CCA) patients (pts) treated with novel targeted therapies after extended molecular profiling on liquid biopsies
Presenter: Umair Mahmood
Session: Poster session 17
123P - Artificial intelligence (AI)-powered analysis of human epidermal growth factor receptor-2 (HER2) and tumor-infiltrating lymphocytes (TILs) in advanced biliary tract cancer (BTC)
Presenter: Gwangil Kim
Session: Poster session 17
124P - Clinicopathological nomogram for predicting fibroblast growth factor receptor 2 (FGFR2) gene fusion/rearrangement (F/R) in intrahepatic cholangiocarcinoma (iCCA)
Presenter: Maria Bensi
Session: Poster session 17
125P - Real-world treatment patterns in patients with biliary tract cancer (BTC): Retrospective chart review survey in Europe (GARNET-2)
Presenter: John Bridgewater
Session: Poster session 17